ProCE Banner Activity

1-Yr Follow-up of Phase II Study of Neoadjuvant Cemiplimab for Stage II-IV Cutaneous Squamous Cell Carcinoma

Conference Coverage

Updated data from a single-arm phase II study of neoadjuvant cemiplimab for patients with stage II-IV resectable cutaneous squamous cell carcinoma showed association with a 12-month EFS rate of 89%.

Released: October 25, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc